Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Using publicly available data from The Cancer Genome Atlas, an amplification and gain of copy number of IGF1R was observed in 38% of triple-negative breast tumors (n=82), 26% of estrogen receptor (ER)-negative tumors (n=174) and 10% of ER-positive tumors (n=594).
|
31289559 |
2019 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We observed an association between insulin treatment and increased p-mTOR and IGF1R expression of breast tumors, especially in premenopausal women.
|
29486734 |
2018 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We first determined that GPER is co-expressed with IGF1R and with the vessel marker CD34 in human breast tumors (n = 4972).
|
29212519 |
2017 |
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This provides a rationale for the combined targeting of p110α with IGF1R or p110β in patients with breast tumors harboring PIK3CA mutations.
|
27048245 |
2016 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The aim of this study was to assess whether IGF-1R expression of breast tumors changes during neoadjuvant therapy and to study whether these changes were associated with survival.
|
25680198 |
2015 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Overexpression of IGF1R and FAK are closely associated with metastatic breast tumors.
|
25749031 |
2015 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The feasibility and prognostic value of analyzing IGF1R gene expression using FFPE samples was evaluated in a cohort of 260 primary breast tumors.
|
21990036 |
2012 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Increased insulin-like growth factor-1 receptor mRNA expression predicts poor survival in immunophenotypes of early breast carcinoma.
|
21057462 |
2011 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Alterations in RNA-binding activities of IRES-regulatory proteins as a mechanism for physiological variability and pathological dysregulation of IGF-IR translational control in human breast tumor cells.
|
18452152 |
2008 |
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
To evaluate the impact of BRCA1 mutations on IGF-IR gene expression, we performed an immunohistochemical analysis of IGF-IR in primary breast tumors from BRCA1 mutation carriers and non-carriers.
|
17766039 |
2007 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Down-regulation of IGF-IR using small, interfering, hairpin RNA (siRNA) inhibits growth of human lung cancer cell line A549 in vitro and in nude mice.
|
17196841 |
2007 |
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast cancer survival among Chinese women: a report from the Shanghai Breast Cancer Study.
|
17063263 |
2007 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells.
|
17525128 |
2007 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Expression patterns of insulin-like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survival.
|
17066319 |
2007 |
Mammary Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
LHGDN |
Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth.
|
16648580 |
2006 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1.
|
16827799 |
2006 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Type I insulin-like growth factor receptor over-expression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells.
|
16584539 |
2006 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.
|
16037379 |
2005 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Transactivation of CXCR4 by the insulin-like growth factor-1 receptor (IGF-1R) in human MDA-MB-231 breast cancer epithelial cells.
|
16172123 |
2005 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Insulin-like growth factor I (IGF-I) stimulates proliferation but also increases caspase-3 activity, Annexin-V binding, and DNA-fragmentation in human MG63 osteosarcoma cells: co-activation of pro- and anti-apoptotic pathways by IGF-I.
|
14710359 |
2004 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer.
|
15595626 |
2004 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo.
|
14710366 |
2004 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: biology and therapeutic relevance.
|
12884909 |
2003 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The IGF-IR and the ER are co-expressed in breast tumors.
|
10791772 |
2000 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Subgroup analysis revealed that, for early breast tumor relapses (within 4 years of initial breast tumor diagnosis), elevated levels of IGF-IR were strongly associated with IBTR (P = 0.004) but IGF-IR expression was not prognostic for IBTR from breast cancer patients with late relapses (P was not significant).
|
9242428 |
1997 |